share_log

Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price Target

Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price Target

坎託·菲茨傑拉德重申增持Mirum Pharmicals,維持35美元的目標股價
Benzinga ·  02/29 13:36

Cantor Fitzgerald analyst Josh Schimmer reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and maintains $35 price target.

坎託·菲茨傑拉德分析師喬什·希默重申米魯姆製藥公司(納斯達克股票代碼:MIRM)增持,目標股價維持35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論